In 2009, by acquiring Wyeth, we became a more diversified company, offering a wider range of high-quality products for people and animals. These include vaccines to prevent disease, biological and pharmaceutical therapies to treat illnesses, technologies to deliver medicines, and iconic brands in consumer health and nutrition, all offered across developed and emerging markets.
We are well-known for a number of widely prescribed therapies, including Lipitor, Viagra, Lyrica, Enbrel and Celebrex. We are moving quickly in oncology, with breakthrough treatments such as Sutent. But we do more than treat disease. We help prevent it through our vaccines, and through medicines such as Chantix (marketed outside the U.S. as Champix), the world's leading prescription medicine for smoking cessation. We also market hundreds of entries in the fastest-growing segment of the pharmaceutical business—generic medicines.
In addition, our roster of trusted consumer brands includes Advil, Centrum, Robitussin and ChapStick, as well as the GOLD line of infant and toddler nutritional products. We offer suites of animal medicines that support livestock farming and keep companion animals healthy and strong. We have Capsugel, a global leader in creating innovative dosage forms for the pharmaceutical and dietary supplement industries.
Our products are valuable at all stages of life. Our work is profound and felt by every person who, because of our offerings, is able to maintain or reclaim well-being and quality of life. And with a pipeline expanded through the Wyeth acquisition, we feel confident that a greater number of essential and life-affirming products are on their way.
Lipitor, the No. 1 prescribed branded cholesterol-lowering medication in the world, also remains one of the most studied prescription medicines of any kind. A study presented in 2009 at the American College of Cardiology's Annual Scientific Session showed that among patients aged 65 and older with established coronary heart disease, Lipitor, when prescribed at 80 milligrams, significantly reduced the relative risk of a first cardiovascular event by 23 percent and provided significant reductions in the risk of subsequent second, third and fourth cardiovascular events over a period of five years, compared to Lipitor at 10 milligrams. The more than 400 ongoing or completed studies involving Lipitor have included over 80,000 patients.
We continued to leverage Pfizer's innovative portfolio of patent-protected products, such as Champix, Sutent and Lyrica, to improve and maintain the health of patients in new markets. Key product launches include: Champix in Egypt, Algeria and Ecuador; Lyrica (fibromyalgia indication) in Venezuela, Brazil, Thailand, Israel and Colombia; Toviaz in Poland and Israel; Caduet in Russia; and Sutent in Pakistan.
Our Animal Genetics business has introduced several new products, including three new genetic defect tests for cattle and a new 56-marker panel that improves cattle producers' decision-making abilities for selection for traits of feed efficiency, marbling and tenderness.
Pfizer is investing in technology to improve the clinical benefit of our products and to deliver better patient management through tools that can predict and diagnose diseases, research patient outcomes, or assist in patient compliance and post-treatment monitoring. We are also in search of physician-directed and patient-managed diagnostic tools for better patient monitoring.
In the European Union:
Pfizer medicines help to treat and prevent a range of conditions—from the common to the most challenging. This tool allows you to learn more about a specific product marketed in the U.S. by searching alphabetically using the product name or a disease or condition.Go to the Site
Pfizer Animal Health now includes Fort Dodge.Go to the Site
Share stories and see how patients are taking control of their heart health with the statin that revolutionized the industry.Go to the Site